Datavault AI (NASDAQ: DVLT) expanded its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS) to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The expanded relationship is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
To view the full press release, visit https://ibn.fm/vBAxH
About Datavault AI Inc.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
At a glance
- Company
- Datavault AI Inc.
- Ticker
- NASDAQ: DVLT
- Announcement
- Partnership
Key figures
- DataMEDS common stock stake to be received upon closing
- approximately 19.9%
Products and programs
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
Datavault AI says it has broadened its licensing arrangement with DataMeds AI to cover commercial healthcare, healthspan and wellness, in addition to pharmaceutical distribution. The companies intend the expanded scope to support patient-directed access to and monetization of health information, as well as tokenization of real-world assets across pharmacies, medical and laboratory settings, and wearable devices. Datavault AI will receive common shares equal to approximately 19.9% of DataMEDS’ outstanding common stock when previously announced related transactions close. This replaces preferred shares that had been contemplated in the original arrangement for tax optimization purposes. The companies say the expansion will bring Datavault AI’s technology into healthcare and enable new models for patient-controlled data transactions. The agreement references a behavioral healthcare patent portfolio involving medical logistics, population health using IoT, and AI-based remote patient monitoring.
Key takeaways
- The amended licensing agreement extends PharmacyChain technology into commercial healthcare, healthspan and wellness applications.
- Datavault AI is to receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of related transactions.
- The expanded scope covers patient-controlled health data and applications across pharmacy, medical, laboratory and wearable environments.
- The companies cite a patent portfolio addressing medical logistics, IoT population health and AI-driven remote patient monitoring.
SEC filings
Earlier from Datavault AI Inc.
- Datavault AI (NASDAQ: DVLT) Advances NIL Debit Card Initiative, Names Ronald Goldstein to Lead Sports Licensing
- Datavault AI (NASDAQ: DVLT) Sets August 4 Analyst Day to Showcase Blockchain and AI Strategy
- Datavault AI (NASDAQ: DVLT) Selects Fiserv for Embedded Banking and Payments
- Datavault AI (NASDAQ: DVLT) Targets Tokenization, Edge AI Expansion in Q3 2026
- Datavault AI (NASDAQ: DVLT) Appoints Barry Childe as Chief Information Security Officer
